PT4010322T - Formas no estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4- tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1- (neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e suas utilizações - Google Patents
Formas no estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4- tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1- (neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e suas utilizaçõesInfo
- Publication number
- PT4010322T PT4010322T PT197585896T PT19758589T PT4010322T PT 4010322 T PT4010322 T PT 4010322T PT 197585896 T PT197585896 T PT 197585896T PT 19758589 T PT19758589 T PT 19758589T PT 4010322 T PT4010322 T PT 4010322T
- Authority
- PT
- Portugal
- Prior art keywords
- neopentylamino
- pentanamide
- tetrahydronaphthalen
- propan
- imidazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/045948 WO2021029854A1 (en) | 2019-08-09 | 2019-08-09 | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4010322T true PT4010322T (pt) | 2025-12-16 |
Family
ID=67734850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197585896T PT4010322T (pt) | 2019-08-09 | 2019-08-09 | Formas no estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4- tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1- (neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e suas utilizações |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP4722197A1 (pt) |
| JP (1) | JP7608435B2 (pt) |
| KR (1) | KR102772889B1 (pt) |
| CN (1) | CN114555562A (pt) |
| AR (1) | AR119614A1 (pt) |
| AU (1) | AU2019461090B2 (pt) |
| BR (1) | BR112022002392A2 (pt) |
| CA (1) | CA3150424A1 (pt) |
| CO (1) | CO2022002731A2 (pt) |
| DK (1) | DK4010322T3 (pt) |
| FI (1) | FIC20260011I1 (pt) |
| HR (1) | HRP20251641T1 (pt) |
| IL (1) | IL290428A (pt) |
| LT (1) | LT4010322T (pt) |
| MX (1) | MX2022001743A (pt) |
| NL (1) | NL301374I2 (pt) |
| NO (1) | NO2026017I1 (pt) |
| PE (1) | PE20221252A1 (pt) |
| PT (1) | PT4010322T (pt) |
| RS (1) | RS67562B1 (pt) |
| WO (1) | WO2021029854A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115916188A (zh) * | 2020-03-13 | 2023-04-04 | 斯普林渥克斯治疗有限公司 | 尼罗司他与bcma定向疗法的组合疗法及其用途 |
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| US11504354B1 (en) * | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| EP4436958A1 (en) | 2021-11-23 | 2024-10-02 | Teva Pharmaceuticals International GmbH | Solid state forms of nirogacestat salts |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| JP2026508907A (ja) | 2023-03-09 | 2026-03-13 | ▲蘇▼州科睿思制▲葯▼有限公司 | ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途 |
| WO2026018210A1 (en) | 2024-07-19 | 2026-01-22 | Assia Chemical Industries Ltd. | Solid state forms of nirogacestat dihydrochloride salt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| WO2019053727A1 (en) * | 2017-09-18 | 2019-03-21 | Ramot At Tel-Aviv University Ltd. | REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH |
-
2019
- 2019-08-09 KR KR1020227007648A patent/KR102772889B1/ko active Active
- 2019-08-09 CN CN201980100044.2A patent/CN114555562A/zh active Pending
- 2019-08-09 PE PE2022000224A patent/PE20221252A1/es unknown
- 2019-08-09 EP EP25213077.8A patent/EP4722197A1/en active Pending
- 2019-08-09 LT LTEPPCT/US2019/045948T patent/LT4010322T/lt unknown
- 2019-08-09 EP EP19758589.6A patent/EP4010322B1/en active Active
- 2019-08-09 HR HRP20251641TT patent/HRP20251641T1/hr unknown
- 2019-08-09 CA CA3150424A patent/CA3150424A1/en active Pending
- 2019-08-09 JP JP2022508525A patent/JP7608435B2/ja active Active
- 2019-08-09 DK DK19758589.6T patent/DK4010322T3/da active
- 2019-08-09 PT PT197585896T patent/PT4010322T/pt unknown
- 2019-08-09 BR BR112022002392A patent/BR112022002392A2/pt unknown
- 2019-08-09 AU AU2019461090A patent/AU2019461090B2/en active Active
- 2019-08-09 WO PCT/US2019/045948 patent/WO2021029854A1/en not_active Ceased
- 2019-08-09 IL IL290428A patent/IL290428A/en unknown
- 2019-08-09 MX MX2022001743A patent/MX2022001743A/es unknown
- 2019-08-09 RS RS20251306A patent/RS67562B1/sr unknown
-
2020
- 2020-08-06 AR ARP200102241A patent/AR119614A1/es unknown
-
2022
- 2022-03-09 CO CONC2022/0002731A patent/CO2022002731A2/es unknown
-
2026
- 2026-03-26 NO NO2026017C patent/NO2026017I1/no unknown
- 2026-03-30 NL NL301374C patent/NL301374I2/nl unknown
- 2026-04-07 FI FIC20260011C patent/FIC20260011I1/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555562A (zh) | 2022-05-27 |
| LT4010322T (lt) | 2025-12-29 |
| MX2022001743A (es) | 2022-05-10 |
| BR112022002392A2 (pt) | 2022-04-26 |
| PE20221252A1 (es) | 2022-08-16 |
| EP4010322B1 (en) | 2025-11-05 |
| EP4010322A1 (en) | 2022-06-15 |
| NL301374I2 (nl) | 2026-07-13 |
| AR119614A1 (es) | 2021-12-29 |
| CO2022002731A2 (es) | 2022-05-20 |
| HRP20251641T1 (hr) | 2026-02-13 |
| AU2019461090A1 (en) | 2022-03-17 |
| EP4722197A1 (en) | 2026-04-08 |
| KR102772889B1 (ko) | 2025-02-26 |
| AU2019461090B2 (en) | 2026-06-18 |
| JP2022553479A (ja) | 2022-12-23 |
| IL290428A (en) | 2022-07-01 |
| RS67562B1 (sr) | 2026-01-30 |
| FIC20260011I1 (fi) | 2026-04-07 |
| WO2021029854A1 (en) | 2021-02-18 |
| KR20220062510A (ko) | 2022-05-17 |
| JP7608435B2 (ja) | 2025-01-06 |
| NO2026017I1 (no) | 2026-03-26 |
| DK4010322T3 (da) | 2025-12-15 |
| CA3150424A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4010322T1 (sl) | Trdne oblike (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol- 4-il)pentanamida in njegova uporaba | |
| LT4010322T (lt) | (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil- 1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamido kieto pavidalo formos ir jų panaudojimas | |
| IL281024A (en) | Pharmaceutical preparations containing N–(3,5–DIMETHOXYPHENYL)–N'–(1–METHYLETHYL)–N–[3–(1–METHYL–1H–PYRAZOL–4–YL)QUINOXALIN–6–YL]ETHANE–1, 2-DIAMINE | |
| ZA202211870B (en) | Imidazolidinone derivatives and medical use thereof | |
| IL288996B2 (en) | Aminopyrimidine amide autophagy inhibitors and methods of using them | |
| EP1608361A4 (en) | COMPOSITIONS OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AND 5-HT1B / 1 D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINS | |
| IL276823A (en) | Casein formulations and their use | |
| MX2016012365A (es) | Combinaciones. | |
| IL310209A (en) | ROCK2 inhibitors and their uses | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| MX2020005771A (es) | Composicion y metodo para tratar el linfoma periferico de linfocitos t y el linfoma cutaneo de linfocitos t. | |
| IL290087B2 (en) | Modified aminoheteroaryls and their use as DES1 inhibitors and/or antifibrotic agents | |
| MX2024002590A (es) | Sintesis de nirogacestat. | |
| IL305789A (en) | USP30 inhibitors and uses thereof | |
| IL313081A (en) | New HDAC inhibitors and their medical use | |
| IL311733A (en) | Hydrochloride salt of inupdanant, pharmaceutical preparations and methods of using it | |
| EP3843742A4 (en) | CD73 INHIBITORS AND THEIR THERAPEUTIC USES | |
| WO2021080931A8 (en) | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use | |
| ZA201600006B (en) | Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof | |
| EP3844289A4 (en) | COMPOSITION AND USE OF CAS PROTEIN INHIBITORS | |
| MX2020007494A (es) | Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. | |
| HK40111933A (en) | Rock2 inhibitors and uses thereof | |
| HUP2300462A1 (hu) | Imidazol-származékok és alkalmazásuk antifibrotikus szerként | |
| HK40077223A (en) | Equine esomeprazole formulations and methods of use | |
| HK1242618A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |